ArticleCancer drug resistance (Alhambra, Calif.)2022
Emerging insights to lung cancer drug resistance.
Article in Cancer drug resistance (Alhambra, Calif.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Application of pleural effusion cell blocks for immunohistochemistry and EGFR gene mutation testing for advanced lung cancer.Experimental and therapeutic medicine · 2026Article
- scDrugMap: benchmarking large foundation models for drug response prediction.Nature communications · 2025Article
- QSAR machine learning-guided discovery of renieramycin right-half derivatives with cytotoxic activity against NSCLC cells.Scientific reports · 2025Article
- Research Progress on the Structure-activity Relationship and Mechanism of Flavonoid Derivatives in the Treatment of Lung Cancer.Molecules (Basel, Switzerland) · 2025Review
- Targeting the inhibitors of apoptosis proteins (IAPs) to combat drug resistance in cancers.Frontiers in pharmacology · 2025Review
- Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment.Cancers · 2023Review
- An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the malignant tumor with the highest morbidity and mortality in China, with non-small cell lung cancer (NSCLC) accounting for 80%-85% of cases. Nowadays, the treatment pattern of NSCLC has evolved toward precision management with the development of molecular targeted therapy and immunotherapy. However, the median overall survival for patients with metastatic NSCLC, unfortunately, remains less than three years. Drug resistance is the bottleneck to preventing drugs from playing a further role, and the mechanistic study of drug resistance is the prerequisite for new regimen development. This Special Issue pays special attention to drug resistance in the treatment of NSCLC. We received and published several excellent articles regarding this topic. We hope that, through this Special Issue, we can have a deep understanding of the existing problems, the underlying mechanism, and the future solutions and that the publication of this Special Issue can bring some inspiration to readers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.